Second cohort following patients entering a multidisciplinary care pathway for post-COVID syndromes (SyPoCo2)
Second Prospective Cohort of Patients Entering the Multidisciplinary Care Pathway for Post-Covid Syndromes - SyPoCo2 Cohort
This project will test whether linking long COVID patients' symptoms with blood immune and molecular markers can find biomarkers and possible treatment targets.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 2 sites (Pierre-Bénite and 1 other locations) |
| Trial ID | NCT07356570 on ClinicalTrials.gov |
What this trial studies
SyPoCo2 is an observational cohort enrolling adults referred to specialized post-COVID care pathways in the Hospices Civils de Lyon system. Participants provide blood samples and detailed clinical information so researchers can correlate symptom patterns with immunological and molecular data. The goal is to identify prognostic biomarkers and signals that could point to therapeutic targets. Data will be analyzed to define clinical profiles and molecular signatures associated with persistent post-COVID symptoms.
Who should consider this trial
Good fit: Adults (≥18) with documented SARS-CoV-2 infection who have persistent or complex post-COVID symptoms and are referred to the EPSILON pathway or the post-COVID rehabilitation unit, non-institutionalized, and expected to survive more than six months are ideal candidates.
Not a fit: People without confirmed SARS-CoV-2 infection, with uncontrolled comorbidities, who are pregnant or breastfeeding, under legal protection or deprived of liberty, not covered by the French national health insurance system, or institutionalized are not eligible and would not benefit from participation.
Why it matters
Potential benefit: If successful, the work could produce blood-based markers that help predict who will have prolonged symptoms and suggest targets for future treatments.
How similar studies have performed: Previous observational cohorts have identified immune and molecular signals linked to long COVID but no universally validated prognostic biomarkers or approved targeted therapies have yet been established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented SARS-CoV-2 infection * Persistent or complex post-COVID symptoms lasting more than 4 weeks or more than 3 months * Patient referred to the EPSILON pathway or to the post-COVID rehabilitation unit * Age ≥ 18 years * Non-institutionalized * Expected survival greater than 6 months Exclusion Criteria: * Refusal to participate or to share data * Uncontrolled comorbidities * Pregnant or breastfeeding women * Persons under legal protection or deprived of liberty * Not affiliated with the French national health insurance system
Where this trial is running
Pierre-Bénite and 1 other locations
- Service Pneumologie aigue spécialisée et cancérologie thoracique — Pierre-Bénite, France (Recruiting)
- Hôpital Henry Gabrielle-HCL — Saint-Genis-Laval, France (Recruiting)
Study contacts
- Study coordinator: Sébastien Couraud, Pr
- Email: Sebastien.couraud@chu-lyon.fr
- Phone: 04 78 86 44 01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.